Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.
Diabetic patients are at a higher risk of carcinogenesis and death from cancer, including colorectal cancer, than healthy individuals. The efficacy of cancer chemotherapy in the diabetic condition remains unclear. In this study, we investigated the efficacy of anticancer agents oxaliplatin and fluorouracil in streptozotocin (STZ)-treated hyperglycemic mice. Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks. Tumor growth was delayed in STZ-treated mice compared to control mice. The tumor volume was significantly smaller after treatment with FOLFOX in control mice, but not in STZ-treated mice. Despite delayed tumor growth, and regardless of whether they received treatment, survival was shorter in STZ-treated mice than in control mice. Cancer chemotherapy with oxaliplatin and fluorouracil was less effective and survival was shorter in hyperglycemia.